According to Mesoblast 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.181577. At the end of 2022 the company had a P/E ratio of 0.0797.
Year | P/E ratio | Change |
---|---|---|
2022 | 0.0797 | -101.26% |
2021 | -6.31 | -34.96% |
2020 | -9.70 | -2.3% |
2019 | -9.93 | 115.99% |
2018 | -4.60 | -70.74% |
2017 | -15.7 | -79.11% |
2016 | -75.2 | 1453.08% |
2015 | -4.84 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | -3.33 | -1,935.77% | Bahamas |
NRC Health
NRC | 26.4 | 14,413.35% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.